

Tel: 012-8072744

Fax: +27-12-8072747

E-mail: [office@sascro.org](mailto:office@sascro.org)

Web : [www.sascro.org](http://www.sascro.org)

## **SASCRO Statement on the use of Prostate Radioactive Ligand Therapy**

**Prostate Radioactive Ligand Therapy should not be administered to patients outside ethically approved and formal clinical trials.**

- SASCRO supports the conduct of clinical trials which are ethically approved and with informed patient consent.
- Prostate radioactive ligand therapy (PRLT) is an investigational approach for the treatment of metastatic castrate resistant prostate cancer. This should be indicated in the patient's consent.
- Currently there is limited clinical data on both the efficacy and toxicity of PRLT. Its use is not included in international guidelines.
- PRLT must be considered in the light of the recent significant advances in the treatment of metastatic castrate resistant prostate cancer. A variety of new agents have been shown in prospective randomised clinical trials to both increase patient survival and the quality of life.
- SASCRO believes all patients with metastatic castrate resistant prostate cancer should be under the care of an oncologist with experience in the use of proven therapies, and who can counsel patients on participation in investigational studies.

SASCRO Executive Committee

28 Mar 2018